CTNM Stock — Contineum Therapeutics Inc.: Cash, EV, Pipeline

Share price

$13.53

Market cap

$509.0M

Cash

$236.6M

Enterprise value

$272.4M

Balance sheet

Cash	$236.6M
Debt	$0.0M
Net cash	$236.6M
Enterprise value	$272.4M
Basic shares	37.5M shares
Fully diluted shares	39.9M shares
Fully diluted market cap	$540.5M
Cash per share	$6.31

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading CTNM daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jun 12 - Jul 24	PIPE-791	Phase 2	Idiopathic Pulmonary Fibrosis	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

PIPE-791

Phase 2 · Active Modality: small molecule (oral, brain-penetrant)

Target LPAR1

Partnerships Wholly-owned; Company retains worldwide rights to LPAR1 programs

Indications

Idiopathic pulmonary fibrosis (IPF) (Phase 2)
Chronic pain (chronic osteoarthritic pain / chronic low back pain) (Phase 1)

Status note LPAR1 inhibitor. PROPEL-IPF global Phase 2 dosing initiated Q1 2026. Phase 1b PET trial completed September 2025; Phase 1b in chronic pain completed April 2026.

PIPE-307

Phase 2 · Active Modality: small molecule (oral)

Aliases JNJ-89495120

Target M1R (muscarinic type 1 receptor)

Partnerships Janssen Pharmaceutica NV (Johnson & Johnson): exclusive worldwide license for development, manufacture and commercialization (February 2023); J&J leads development; Company has opt-in right to co-fund Phase 3 development

Indications

Major depressive disorder (MDD) (Phase 2)
Relapsing-remitting multiple sclerosis (RRMS) (Phase 2)

Status note M1R inhibitor; renamed JNJ-89495120 by J&J. MOONLIGHT-1 Phase 2 in MDD missed its primary endpoint (MADRS change from baseline at Day 5 vs placebo), reported September 14, 2026; J&J evaluating the full data including prespecified exploratory endpoints to inform next steps. VISTA Phase 2 in RRMS completed 2025 without benefit.

CTX-343

Stage not disclosed · Active

Target LPA1R

Partnerships not disclosed

Indications

not disclosed (Stage not disclosed)

Status note Strategic decision to defer further clinical development until funding obtained.

Per-asset detail extracted from the 10-Q filed 2026-07-30. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	PIPE-791
Lead indication	Idiopathic pulmonary fibrosis
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07284459	Phase 2	Recruiting	Sponsor	CTNM	—	Idiopathic Pulmonary Fibrosis	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Contineum Therapeutics on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Ikarian Capital	807,874	no change	2.17%	2026-08-14
ADAR1 Capital Management	278,961	+2,300	0.21%	2026-08-14
Sphera Biotech	183,475	+10,000	0.43%	2026-08-14
Baker Bros. Advisors	0	-1,420,838	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

CTNM — Contineum Therapeutics Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders